Pharma & biotech

Novo CEO spies new pricing model in EU

CEO of Novo Nordisk Lars Fruergaard Jørgensen will be the pharmaceutical industry’s ear to the ground as the industry’s fundamental EU framework is revised. He tells MedWatch about the strategy, which he hopes will bolster European life science, and a new pricing mechanism he hopes will ensure better market access.
CEO of Novo Nordisk Lars Fruergaard Jørgensen sees a need to challenge current technological evaluations a pricing mechanisms if the European market is to become attractive once again, and has spotted an opportunity within the EU | Photo: Valdemar Ren
CEO of Novo Nordisk Lars Fruergaard Jørgensen sees a need to challenge current technological evaluations a pricing mechanisms if the European market is to become attractive once again, and has spotted an opportunity within the EU | Photo: Valdemar Ren
by peter thomsen, eu correspondent for watch medier, translated by catherine brett & daniel pedersen

BRUSSELS – At first, the signs were small, Lars Fruergaard Jørgensen remembers.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs